These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9679959)

  • 1. Interstitial methotrexate kinetics in primary breast cancer lesions.
    Müller M; Brunner M; Schmid R; Mader RM; Bockenheimer J; Steger GG; Steiner B; Eichler HG; Blöchl-Daum B
    Cancer Res; 1998 Jul; 58(14):2982-5. PubMed ID: 9679959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients.
    Müller M; Mader RM; Steiner B; Steger GG; Jansen B; Gnant M; Helbich T; Jakesz R; Eichler HG; Blochl-Daum B
    Cancer Res; 1997 Jul; 57(13):2598-601. PubMed ID: 9205062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of microdialysates from cancer patients by capillary electrophoresis.
    Mader RM; Brunner M; Rizovski B; Mensik C; Steger GG; Eichler HG; Müller M
    Electrophoresis; 1998 Nov; 19(16-17):2981-5. PubMed ID: 9870399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
    Devineni D; Klein-Szanto A; Gallo JM
    Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral methotrexate kinetics in a patient with intracranial anaplastic ependymoma.
    Geis T; Peters O; Friedrich M; Dränert E; Wolff JE
    Pediatr Blood Cancer; 2004 Jul; 43(1):78-80. PubMed ID: 15170895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
    Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
    Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset delayed excretion of methotrexate.
    Pauley JL; Panetta JC; Schmidt J; Kornegay N; Relling MV; Pui CH
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):146-52. PubMed ID: 15148625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
    Yuan SH; Ge WH; Huo J; Wang XH
    Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow.
    Belur LR; Boelk-Galvan D; Diers MD; McIvor RS; Zimmerman CL
    Cancer Res; 2001 Feb; 61(4):1522-6. PubMed ID: 11245460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate for intraocular lymphoma.
    Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
    Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit.
    Dukic S; Kaltenbach ML; Gourdier B; Marty H; Vistelle R
    Pharm Res; 1998 Jan; 15(1):133-8. PubMed ID: 9487560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: a study in breast cancer patients.
    Müller M; Bockenheimer J; Zellenberg U; Klein N; Steger GG; Eichler HG; Mader RM
    Breast Cancer Res Treat; 2000 Apr; 60(3):211-7. PubMed ID: 10930108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
    Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
    Sane R; Wu SP; Zhang R; Gallo JM
    Drug Metab Dispos; 2014 Apr; 42(4):537-40. PubMed ID: 24464805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone.
    Fox RI; Morgan SL; Smith HT; Robbins BA; Choc MG; Baggott JE
    Rheumatology (Oxford); 2003 Aug; 42(8):989-94. PubMed ID: 12730515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.